CYP1B1 and neoplasm: Furthermore, we also probed insight into the immune subtype, molecular subtype, tumor mutation burden (TMB), microsatellite instability (MSI), neoantigen, and immune-related pathways mediated by CYP1B1, which may provide a promising predictor and molecular target for clinical immune treatment.